TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
TCL Archive In Brief: Recompetition Of Frederick Contract Flops, As Others Leave The Field To Litton-Bionetics April 15, 1977
TCL Archive Talking Back: FDA Faces Challenges Over Avastin & Prostate Cancer Prevention January 21, 2011
